Company Active LTD

Company profile

Nonacus Limited

UK company 09590278, incorporated on 14 May 2015.

Non-Invasive Healthcare | cfDNA Products | Nonacus

Non-Invasive Healthcare - Helping genomic healthcare professionals and researchers improve patient care through validated cell-free DNA solutions.

Company number
09590278
Incorporated
14 May 2015
Companies House status
Active

Company identity

Founded / incorporated
14 May 2015

Company number 09590278

Verify at Companies House
Legal name
NONACUS LIMITED
Company type
LTD
Region
Unknown
Registered address
Unknown
Insolvency history
No

Corporate ownership

Updated 07 Jul 2026 09:49

1 level 1 ultimate controller
1
Company Active LTD
Nonacus Limited
CRN 09590278
2
Direct and ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

4 events
01 Sep
2026

Legacy

Accounts PDF pending

PARENT_ACC | Transaction MzU0MTg4NzU5OWFkaXF6a2N4 | Paper/PDF filed

Published 02 Sep 2026 23:20

01 Sep
2026

Accounts With Accounts Type Audit Exemption Subsiduary

Accounts PDF pending

AA | Transaction MzU0MTg4ODM4OGFkaXF6a2N4 | Paper/PDF filed

Published 02 Sep 2026 23:08

16 Jul
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzUzMzExMDczNGFkaXF6a2N4

Published 16 Jul 2026 03:34

14 May
2015

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2020
Funded years
2020, 2026
Age at first award
5 years

Projects

2026 Lead participant

GALEAS Bladder: Transforming Cancer Detection in the NHS

9 Apr 2026 to 9 Apr 2029

Awarded
£2,500,000
Total cost £2,677,662

GALEAS Bladder is a simple, non-invasive urine test to detect the presence of bladder cancer. Developed in partnership with researchers at the University of Birmingham, UK, the test leverages ultra-sensitive targeted Next Generation Sequencing (NGS) to interrogate the key somatic mutations found across all grades and stages of bladder cancer. This project...

2020 Feasibility Studies Lead participant

Rapid WGS of SARS-CoV-2 and respiratory viruses for disease surveillance using nanopore sequencing

1 Jun 2020 to 30 Nov 2020

Awarded
£49,591
Total cost £49,591

The current COVID-19 pandemic requires advanced diagnostics assays which can be rapidly deployed across many laboratories, globally and to allow for both diagnostic COVID-19 testing but additionally a for surveillance and monitoring of the disease within and between populations by public health institutions. To date ourselves and others have developed and...

Product types

Feasibility Studies